Phase II trial with a recombinant humanized anti-CD33 monoclonal antibody (HuM195) [lintuzumab] in patients with high risk primary myelodysplastic syndromes.

Trial Profile

Phase II trial with a recombinant humanized anti-CD33 monoclonal antibody (HuM195) [lintuzumab] in patients with high risk primary myelodysplastic syndromes.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2013

At a glance

  • Drugs Lintuzumab (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jul 2012 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 23 Jul 2008 Planned patient number is 25 as reported by ClinicalTrials.gov.
    • 02 May 2007 Updated from CT.gov, DMS changes 13/2/07
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top